Virbac 将来の成長

Future 基準チェック /26

Virbac利益と収益がそれぞれ年間10.8%と6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に13.9% 10.6%なると予測されています。

主要情報

10.8%

収益成長率

10.6%

EPS成長率

Pharmaceuticals 収益成長	18.3%
収益成長率	6.0%
将来の株主資本利益率	13.9%
アナリストカバレッジ	Good
最終更新日	04 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

LSE:0NM7 - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,566	185	127	229	7
12/31/2025	1,483	166	107	201	8
12/31/2024	1,397	150	79	172	7
6/30/2024	1,339	141	74	139	N/A
3/31/2024	1,293	131	66	129	N/A
12/31/2023	1,247	121	59	119	N/A
9/30/2023	1,229	120	69	124	N/A
6/30/2023	1,210	119	78	129	N/A
3/31/2023	1,213	121	62	114	N/A
12/31/2022	1,216	122	45	99	N/A
9/30/2022	1,184	120	38	91	N/A
6/30/2022	1,151	119	31	84	N/A
3/31/2022	1,107	116	57	107	N/A
12/31/2021	1,064	113	83	130	N/A
9/30/2021	1,025	137	80	122	N/A
6/30/2021	985	161	77	113	N/A
3/31/2021	960	148	83	116	N/A
12/31/2020	934	136	90	119	N/A
9/30/2020	944	104	106	133	N/A
6/30/2020	953	72	123	146	N/A
3/31/2020	946	62	116	139	N/A
12/31/2019	938	52	109	132	N/A
9/30/2019	921	43	92	119	N/A
6/30/2019	903	34	76	106	N/A
3/31/2019	886	27	63	95	N/A
12/31/2018	869	20	50	84	N/A
9/30/2018	862	8	58	93	N/A
6/30/2018	854	-4	66	103	N/A
3/31/2018	858	-3	N/A	105	N/A
12/31/2017	862	-3	N/A	108	N/A
9/30/2017	871	16	N/A	112	N/A
6/30/2017	879	35	N/A	117	N/A
3/31/2017	876	35	N/A	130	N/A
12/31/2016	872	35	N/A	142	N/A
9/30/2016	861	30	N/A	119	N/A
6/30/2016	850	26	N/A	95	N/A
3/31/2016	851	18	N/A	71	N/A
12/31/2015	853	9	N/A	46	N/A
9/30/2015	846	21	N/A	59	N/A
6/30/2015	839	32	N/A	72	N/A
3/31/2015	806	48	N/A	74	N/A
12/31/2014	773	64	N/A	76	N/A
9/30/2014	752	60	N/A	77	N/A
6/30/2014	730	56	N/A	78	N/A
3/31/2014	733	58	N/A	76	N/A
12/31/2013	736	61	N/A	74	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0NM7の予測収益成長率 (年間10.8% ) は貯蓄率 ( 2.1% ) を上回っています。

収益対市場: 0NM7の収益 ( 10.8% ) UK市場 ( 14.4% ) よりも低い成長が予測されています。

高成長収益: 0NM7の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 0NM7の収益 ( 6% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0NM7の収益 ( 6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0NM7の自己資本利益率は、3年後には低くなると予測されています ( 13.9 %)。

Virbac 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Virbac SA Revises Earnings Guidance for the Fiscal Year 2024

Virbac SA Provides Earnings Guidance for the Year 2024

Virbac SA Confirms Revenue Forecasts for the Year 2023

Virbac SA Provides Revenue Guidance for the Year 2022

Virbac SA Provides Revenue Guidance for the Year 2022

Virbac SA Raises Revenue Guidance for 2021

Recent updates

Virbac SA Revises Earnings Guidance for the Fiscal Year 2024

Virbac Sa Announces Chief Executive Officer Changes

Upcoming dividend of €1.32 per share

Upcoming dividend of €1.32 per share

Upcoming dividend of €1.32 per share

Dividend of €1.32 announced

Full year 2023 earnings released: EPS: €14.40 (vs €14.43 in FY 2022)

Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591).

Full year 2023 earnings released: EPS: €14.40 (vs €14.44 in FY 2022)

Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million.

Virbac SA Provides Earnings Guidance for the Year 2024

Now 20% undervalued

Virbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024

Investor sentiment improves as stock rises 19%

Virbac SA (ENXTPA:VIRP) signed an agreement to acquire Globion India Private Limited from Suguna Foods Private Limited and Lohmann Animal Health GmbH.

Virbac SA (ENXTPA:VIRP) signed an agreement to acquire Globion India Private Limited from Suguna Foods Private Limited and Lohmann Animal Health GmbH.

First half 2023 earnings released: EPS: €8.86 (vs €9.18 in 1H 2022)

Virbac SA Confirms Revenue Forecasts for the Year 2023

Upcoming dividend of €1.32 per share at 0.5% yield

Full year 2022 earnings released: EPS: €14.44 (vs €13.40 in FY 2021)

Virbac SA to Report First Half, 2023 Results on Sep 14, 2023

Virbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023

Investor sentiment deteriorated over the past week

Virbac SA Provides Revenue Guidance for the Year 2022

First half 2022 earnings released: EPS: €9.18 (vs €8.54 in 1H 2021)

Investor sentiment deteriorated over the past week

Upcoming dividend of €1.25 per share

Full year 2021 earnings released: EPS: €13.40 (vs €16.13 in FY 2020)

Virbac SA Provides Revenue Guidance for the Year 2022

Virbac SA (ENXTPA:VIRP) acquired an additional 15% stake in Centrovet group for $17.7 million.

Virbac SA Raises Revenue Guidance for 2021

Upcoming dividend of €0.75 per share

Friulchem S.p.A. (BIT:FCM) signed a preliminary agreement to acquire Business Unit of Virbac SA (ENXTPA:VIRP) for €2.5 million.

Investor sentiment improved over the past week

Virbac SA Revises Earnings Guidance for the Year 2021

Full year 2020 earnings released: EPS €16.29 (vs €6.11 in FY 2019)

Virbac SA Proposes Dividend for the 2020 Financial Year

Virbac SA to Report Fiscal Year 2020 Results on Mar 17, 2021

New 90-day low: €202

Algenex and Virbac Signs International Commercial Licensing Agreement for Crisbio-Based Vaccine in Major Swine Indication

Investor sentiment deteriorated over the past week

New 90-day high: €244

Virbac SA, Annual General Meeting, Jun 21, 2021

New 90-day high: €233

New 90-day high: €223

New 90-day high: €206

First half earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘